New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time. According to Drugs.com, the medication was first approved by the U.S. Food ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...

David J. Phillip/AP The list includes medications for type 2 diabetes, allergic diseases, chronic kidney disease, heart ...

ETNB has a solid financial runway but faces risks from GLP-1 data and competition within the FGF21 space, making it a Hold ...

Others were taking older Novo drugs Saxenda or Victoza, which are both liraglutide, Rybelsus, an oral version of semaglutide, ...